Search results
Results from the WOW.Com Content Network
Insulin lispro, sold under the brand name Humalog among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes. [5] It is delivered subcutaneously either by injection or from an insulin pump .
The long acting insulin is given once (usually glargine, Lantus) or twice (usually detemir, Levemir) daily to provide a base, or basal insulin level. Rapid acting (RA) insulin is given before meals and snacks. A similar profile can be provided using an insulin pump where rapid acting insulin is given as the basal and premeal bolus insulin.
Faster-acting insulins peak quickly and are subsequently metabolized, while longer-acting insulins tend to have extended peak times and remain active in the body for more significant periods. [5] Examples of rapid-acting insulins (peak at ~1 hour) are: [citation needed] Insulin lispro (Humalog) Insulin aspart (Novolog) Insulin glulisine (Apidra)
The cheaper KwikPens pack of five will cost $265.20 and are expected to be available from mid-April. ... molecule as Humalog. Insulin Lispro Injection was also priced 50% lower than the list price ...
This is an ultralong-acting insulin analogue developed by Novo Nordisk, which markets it under the brand name Tresiba. It is administered once daily and has a duration of action that lasts up to 40 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir).
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
This insulin causes body tissues to absorb glucose from the blood and decreases glucose production by the liver. [7] Insulin glargine was patented, but the patent expired in most jurisdictions in 2014. It was approved for medical use in the United States in 2000. [7] It is on the World Health Organization's List of Essential Medicines. [9]
The U.S. Food and Drug Administration has approved a fast-acting diabetes drug called Afrezza for use by adults with Type 1 or Type 2 diabetes. The drug is inhaled into the lungs using a small ...